Tanezumab, identified by the catalog designation 880266-57-9, represents a targeted antibody compound demonstrating significant promise in treating chronic osteoarthritis pain. This modified antibody uniquely targets pain growth element , blocking its function and thereby lessening pain within affected joints . The experimental data surrounding 880266-57-9 highlights its capacity to deliver significant discomfort alleviation while possibly limiting the dependence for conventional analgesics. Further studies are actively underway to completely determine its lasting security and performance.
Comprehending Tanezumab's Part in Ache Alleviation: An Antibody View
Tanezumab, a unique therapeutic approach, offers a distinct pathway in long-term pain management. As a monoclonal antibody, it precisely targets and blocks nerve growth factor (NGF), a important molecule engaged in sensory discomfort signaling. Unlike conventional opioid medications, tanezumab’s protein mechanism allows for a more specific action, potentially reducing the likelihood of some widespread side effects associated with broad pain reduction. However, its body's defense nature necessitates a careful consideration of potential allergic effects and long-term effects when administered within a complete pain therapy plan.
Tanezumab Reagent (880266-57-9): Quality , Quality & Uses
The Tanezumab Compound with the identifier 880266-57-9 is a vital component in various scientific applications, particularly concerning chronic inflammation treatment development. Achieving a high degree of quality is paramount; therefore, rigorous testing protocols are employed to guarantee its fitness for specific use. Our creation procedure Tanezumab humanized antibody focuses on maximizing purity , employing sophisticated filtration techniques to remove contaminants . Typical specifications include a >95% purity assessment as determined by Chromatography and comprehensive testing for biochemical integrity. The main applications revolve around its role as a experimental agent for investigating processes of arthritis progression and next-generation therapeutic interventions .
- Scientific Investigations
- Drug Development
- Mechanism Studies
The Investigation Of Tanezumab:
Tanezumab, identified with the molecular identifier 880266-57-9, represents a innovative therapeutic immunoglobulin targeting nerve factor factor receptor (NGF). The mechanism of action revolves about selectively connecting to NGF, consequently blocking its activity and later communication propagation. Investigators have shown that this molecular molecule offers opportunity for managing severe suffering, particularly in diseases like arthritic conditions and peripheral back discomfort. Additional research are continuing to completely characterize its impact and safety data.
New Advances in Tanezumab Study: Focusing on the The Compound
Current research surrounding tanezumab, a experimental therapeutic compound, are increasingly centered on understanding the role of the identified reagent, the reagent. The discovery and detailed evaluation of the molecular entity seems crucial for improving tanezumab's efficacy and minimizing potential adverse outcomes. Initial results suggest that the reagent plays a key role in tanezumab’s mechanism of action. Additional exploration are required to entirely clarify the reagent’s influence.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}